Associated Papers
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.
Siegel F et al.
Cancer Discovery, 2026
Enhanced HER2 internalization by clathrin-dependent endocytosis in non-small cell lung cancer positive for HER2 mutations.
Shimauchi A et al.
British Journal of Cancer, 2025
Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights.
Nogueira CD et al.
Oncotarget, 2025
Dynamic characterization of circulating tumor DNA in HER2-altered advanced non-small cell lung cancer treated with pyrotinib and apatinib: Exploratory biomarker analysis from PATHER2 study.
Dong Y et al.
Lung Cancer (amsterdam, Netherlands), 2025
RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic NTRK fusions in a real-world standard-of-care setting.
Wallen ZD et al.
Frontiers in Genetics, 2025
Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.
Waliany S et al.
Cancer Medicine, 2024
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients.
Hong L et al.
Npj Precision Oncology, 2024
HER2 mutations in advanced cervical neuroendocrine carcinoma: implications for trastuzumab deruxtecan therapy.
Chao WR et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2024
Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: a retrospective ATLAS cohort study.
Yang G et al.
Discover Oncology, 2024
Discovery of Novel 5,6-Dihydro-4H-pyrido[2,3,4-de]quinazoline Irreversible Inhibitors Targeting Both Wild-Type and A775_G776insYVMA Mutated HER2 Kinases.
Yang L et al.
Journal of Medicinal Chemistry, 2024
A review of HER2 overexpression and somatic mutations in cancers.
Galogre M et al.
Critical Reviews in Oncology/hematology, 2023
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Berko ER et al.
Nature Communications, 2023
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
Harding JJ et al.
Nature Communications, 2023
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review.
Vaghi C et al.
Cancer Treatment Reviews, 2023
Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.
Bosse KR et al.
Cancer Discovery, 2022
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
Cani AK et al.
Molecular Oncology, 2022
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature.
Xu H et al.
World Journal of Surgical Oncology, 2021
Targeting HER2 genomic alterations in non-small cell lung cancer.
Zeng J et al.
Journal of the National Cancer Center, 2021
Distinct genomic profile in h. pylori-associated gastric cancer.
Zhang X et al.
Cancer Medicine, 2021
Non-amplification genetic alterations of HER2 gene in non-small cell lung carcinoma.
Mehta A et al.
Journal of Clinical Pathology, 2021
Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations.
Yang S et al.
Translational Lung Cancer Research, 2021
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing.
Lang GT et al.
Nature Communications, 2020
The efficacy of afatinib in patients with HER2 mutant non-small cell lung cancer: a meta-analysis.
Zhou N et al.
Translational Cancer Research, 2020
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC.
Baraibar I et al.
Critical Reviews in Oncology/hematology, 2020
HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib.
Zhang X et al.
Frontiers in Oncology, 2020
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Wang Y et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2019
Challenges of Providing Concordant Interpretation of Somatic Variants in Non-Small Cell Lung Cancer: A Multicenter Study.
Gao P et al.
Journal of Cancer, 2019
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Robichaux JP et al.
Nature Medicine, 2018
Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.
Wang Y et al.
Bmc Cancer, 2018
Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report.
Park CK et al.
Journal of Korean Medical Science, 2018
Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
Suzawa K et al.
Cancer Science, 2016
Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J et al.
The Oncologist, 2015
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Arcila ME et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
Greulich H et al.
Proceedings of the National Academy of Sciences of the United States of America, 2012
Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain.
Sonobe M et al.
The Journal of Molecular Diagnostics : Jmd, 2006